Quoted by Ryan, Bottom line, ACTC phase II will probably come in first and set the tone for the rest of the stem cell industry.
And, quote by Ryan, "I see more than one company showing interest in at least helping ACT through the final phase III if phase II succeeds."
Sentiment: Strong Buy
That's funny, I thought ACT was dodging calls from potential investing firms. At least for now.
Acan, thats a good thing to know, because besides Lincoln Park Financial the only other firm showing any interest in ACT, is ACT it's self. And why is that? It's because they have yet to show EFFICACY!
At what cost? A majority stake in the profits? Much more dilution?